Literature DB >> 33492962

Novel 18F-Labeled Isonicotinamide-Based Radioligands for Positron Emission Tomography Imaging of Glycogen Synthase Kinase-3β.

Yuhua Zhong1, Shaoxi Yang2, Jianyu Cui2, Jie Wang2, Lin Li2, Yilin Chen2, Junjie Chen2, Pengju Feng3, Shun Huang2, Hongsheng Li2, Yanjian Han2, Ganghua Tang2, Kongzhen Hu2.   

Abstract

Glycogen synthase kinase-3β (GSK-3β), a cytoplasmic serine/threonine protein kinase, is involved in several human pathologies including Alzheimer's disease, bipolar disorder, diabetes, and cancer. Positron emission tomography (PET) imaging of GSK-3β could aid in investigating GSK-3β levels under normal and pathological conditions. In this study, we designed and synthesized fluorinated PET radioligands starting with recently identified isonicotinamide derivatives that showed potent affinity to GSK-3β. After extensive in vitro inhibitory activity assays and analyzing U87 cell uptake, we identified [18F]10a-d as potential tracers with good specificity and high affinity. They were then subjected to further in vivo evaluation in rodent brain comprising PET imaging and metabolism studies. The radioligands [18F]10b-d penetrated the blood-brain barrier and accumulated in GSK-3β-rich regions, including amygdala, cerebellum, and hippocampus. Also, it could be specifically blocked using the corresponding standard compounds. With these results, this work sets the basis for further development of novel 18F-labeled GSK-3β PET probes.

Entities:  

Keywords:  18F-labeled; GSK-3β; PET; brain; isonicotinamide

Year:  2021        PMID: 33492962     DOI: 10.1021/acs.molpharmaceut.0c01133

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  2 in total

1.  PET imaging of glycogen synthase kinase-3 in pancreatic cancer xenograft mouse models.

Authors:  Amanda J Boyle; Andrea Narvaez; Melissa Chassé; Neil Vasdev
Journal:  Am J Nucl Med Mol Imaging       Date:  2022-02-15

Review 2.  Current status and future perspective of radiopharmaceuticals in China.

Authors:  Ji Hu; Hongyu Li; Yanying Sui; Jin Du
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-11-12       Impact factor: 10.057

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.